- Advanced search
- Immuno Portal
- Malaria Portal
Ligand id: 5936
View more information in the IUPHAR Pharmacology Education Project: nintedanib
Molecular properties generated using the CDK
|No information available.|
|Summary of Clinical Use|
|Nintedanib was originally approved as a treatment for idiopathic pulmonary fibrosis. Subsequently it has been approved (by the FDA) to slow pulmonary fuction decline in patients with systemic sclerosis-associated interstitial lung diseases (ILD).
Click here to link to ClinicalTrials.gov current list of nintedanib studies.
In October 2019 the FDA granted Breakthrough Therapy Designation to nintedanib for the treatment of progressive chronic fibrosing ILD, based on preliminary results from the Phase 3 INBUILD trial (NCT02999178).
|Mechanism Of Action and Pharmacodynamic Effects|
|Nintedanib inhibits multiple angiogenic pathways, and appears to also inhibit pathways associated with the fibrotic scarring of the lung observed in idiopathic pulmonary fibrosis (IPF). In tumours inhibition of VEGF receptor (VEGFR), PDGFR and FGFR kinase activity reduces tumour angiogenesis/neo-vascularisation, thereby restricitng tumour expansion . The mechanism in IPF is less clear. See  and  for further information.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)